0001633932
false
A1
0001633932
2023-08-08
2023-08-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
—————————
FORM 8-K
—————————
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August
8, 2023
—————————
ESSA Pharma Inc.
(Exact name of registrant as specified in its charter)
—————————
British Columbia, Canada
(State or other jurisdiction of incorporation) |
001-37410
(Commission File Number) |
98-1250703
(IRS Employer Identification No.) |
|
|
|
Suite 720, 999 West Broadway, Vancouver, British
Columbia, Canada
(Address of principal executive offices) |
V5Z 1K5
(Zip Code) |
Registrant’s telephone number, including area
code: (778) 331-0962
—————————
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of
each class |
Trading
Symbol(s) |
Name of
each exchange on which registered |
Common Shares, no par value |
EPIX |
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
The following information is filed pursuant to Item
2.02, “Results of Operations and Financial Condition.”
On August 8, 2023, ESSA Pharma Inc. (the “Company”)
issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023. A copy of the press release is attached
as Exhibit 99.1 to this Form 8-K.
The information provided under this Item (including
Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 |
Financial Statements and Exhibits. |
|
|
|
(d) Exhibits |
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ESSA PHARMA INC. |
|
|
(Registrant) |
|
|
|
|
|
|
|
|
Date: August 8, 2023 |
|
|
|
|
|
|
|
|
By: |
/s/ David Wood |
|
|
Name: |
David Wood |
|
|
Title: |
Chief Financial Officer |
Exhibit
99.1
ESSA Pharma Provides Corporate Update and Reports
Financial Results for
Fiscal Third Quarter Ended June 30, 2023
Completion of the Phase 1 EPI-7386 combination
study with Xtandi® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the
randomized Phase 2 part of the study
Entered into clinical trial support agreement
with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored
Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin 2H2023
Phase 1b EPI-7386 monotherapy expansion study
in mCRPC patients ongoing
South San Francisco, California and Vancouver, Canada,
August 8, 2023 - ESSA Pharma Inc. (“ESSA”, or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical
company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial
results for the fiscal third quarter ended June 30, 2023. All references to “$” in this release refer to United States dollars,
unless otherwise indicated.
“Over the past months we have ramped up preparations
to initiate the randomized Phase 2 combination study of EPI-7386 and Astellas and Pfizer’s antiandrogen Xtandi® (enzalutamide),
and we expect to complete the Phase 1 part of the study in the coming quarter,” stated David Parkinson, MD, President and CEO of
ESSA. “In the past quarter, we finalized our clinical collaboration with Janssen to evaluate EPI-7386 in combination with Janssen’s
antiandrogens Erleada® (apalutamide) and Zytiga® (abiraterone acetate) in two Phase 1 cohorts,
building on initial Phase 1 clinical data demonstrating promising prostate-specific antigen (“PSA”) declines following combination
treatment. ESSA is in a strong cash position as we advance our EPI-7386 studies, with our cash runway expected to fund operations and
programs through 2025.”
Clinical and Corporate Highlights for the Third
Quarter Ended June 30, 2023
EPI-7386 Clinical Collaborations
| · | The Company is preparing to initiate
the open-label, randomized Phase 2 study of EPI-7386 and Astellas and Pfizer’s antiandrogen Xtandi® (enzalutamide)
in patients with metastatic castration-resistant prostate cancer (“mCRPC”) naïve to second-generation antiandrogens.
The Phase 2 study will assess the anti-tumor activity of EPI-7386 in combination with enzalutamide at the recommended Phase 2 doses versus
single agent enzalutamide at the standard-of-care dose. The study is expected to enroll approximately 120 patients. The Company expects
to complete the Phase 1 part of the study and establish the recommended Phase 2 combination doses (for both EPI-7386 and enzalutamide
when used in combination) in the third calendar quarter of 2023, followed by initiation of the Phase 2 part of the study. |
| · | In April 2023, the Company entered
into a clinical trial support agreement with Janssen Research & Development, LLC (“Janssen”) under which Janssen will
supply apalutamide and abiraterone acetate for a Phase 1 clinical study sponsored and conducted by ESSA evaluating EPI-7386 combination
therapies in two cohorts. The two cohorts will be evaluated as additional cohorts in the Company’s ongoing Phase 1 study of EPI-7386
(Clinical Trials Identifier: NCT04421222). Cohort 1 will assess EPI-7386 in combination with abiraterone acetate plus prednisone in patients
with mCRPC and high-risk metastatic castration-sensitive prostate cancer. Cohort 2 is a Window of Opportunity study in which patients
with non-metastatic castration-resistant prostate cancer (“nmCRPC”) will receive up to 12 weeks of single agent EPI-7386 before
adding standard-of-care apalutamide. ESSA will retain all rights to EPI-7386. The Company expects enrollment to begin in the second half
of calendar 2023. |
EPI-7386 Monotherapy
| · | The Phase 1b EPI-7386 monotherapy
dose expansion study is ongoing and is evaluating two doses/schedules of single agent EPI-7386 in mCRPC patients with less than three
prior lines of therapy, no visceral disease and no prior chemotherapy who have progressed on at least one second-generation antiandrogen.
The Company is also enrolling nmCRPC patients in the Window of Opportunity cohort of the study, in which patients will receive 12 weeks
of EPI-7386 monotherapy treatment before starting standard-of-care therapy. |
Corporate Updates
| · | In June 2023, the Company announced
the appointment of Lauren Merendino, M.B.A., to its Board of Directors. Ms. Merendino is a leading biopharmaceutical executive who brings
over 25 years of commercial experience spanning 20+ disease states, including 15 years of leadership for oncology-specific portfolios. |
Summary Financial Results
| · | Net Loss. ESSA recorded
a comprehensive loss of $7.3 million for the third quarter ended June 30, 2023, compared to a comprehensive loss of $8.8 million for the
third quarter ended June 30, 2022. For the third quarter ended June 30, 2023, this included non-cash share-based payments of $1.2 million
compared to $1.6 million for the prior year, recognized for stock options granted and vesting. The decrease in the third quarter was primarily
attributed to decreases in research and development expenditures and general and administration expenditures in addition to an increase
of $1.2 in interest and other income. |
| · | Research and Development (“R&D”)
expenditures. R&D expenditures for the third quarter ended June 30, 2023 were $6.3 million compared to $6.4 million for the third
quarter ended June 30, 2022 and include non-cash costs related to share-based payments ($599,621 for the third quarter ended 2023 compared
to $872,531 for the third quarter ended 2022). The decrease in R&D expenditures for the year ended June 30, 2023 is the result of
decreased non-cash share-based payments, legal patents and license fees and manufacturing costs related to the Phase 1 clinical trial
of EPI-7386. |
| · | General and administration
(“G&A”) expenditures. G&A expenditures for the third quarter ended June 30, 2023 were $2.6 million compared to
$2.9 million for the third quarter ended June 30, 2022 and include non-cash costs related to share-based payments of $561,452 for the
third quarter ended 2023 compared to $718,469 for the third quarter ended 2022. The decrease in the third quarter is the result of decreased
non-cash share-based payments, salaries and benefits and consulting and subcontractor fees. |
Liquidity and Outstanding Share Capital
At June 30, 2023, the Company
had available cash reserves and short-term investments of $152.5 million reflecting the gross proceeds of the February 2021 financing
of approximately $150.0 million, less operating expenses in the intervening period. The Company’s cash position is expected to be
sufficient to fund current and planned operations through 2025.
As of June 30, 2023, the Company had 44,092,374
common shares issued and outstanding.
In addition, as of June 30, 2023 there were 2,927,477
common shares issuable upon the exercise of warrants and broker warrants. This includes 2,920,000 prefunded warrants at an exercise price
of $0.0001, and 7,477 warrants at a weighted average exercise price of $42.80. There were 8,150,274 common shares issuable upon the exercise
of outstanding stock options at a weighted-average exercise price of $5.05 per common share.
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused
on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com
and follow us on Twitter under @ESSAPharma.
Forward-Looking Statement Disclaimer
This release contains certain information which, as
presented, constitutes "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995
and/or applicable Canadian securities laws. Forward-looking information involves statements that relate to future events and often addresses
expected future business and financial performance, containing words such as "anticipate", "believe", "plan",
"estimate", "expect", and "intend", statements that an action or event "may", "might",
"could", "should", or "will" be taken or occur, or other similar expressions and includes, but is not limited
to, statements regarding the completion of the Phase 1 combination study with enzalutamide and initiation of the randomized Phase
2 part of the study, enrollment in the monotherapy and combination studies, the assessment of anti-tumor activity in the Phase 2 combination
study, the clinical trial support agreement, the supply of apalutamide and abiraterone acetate, the rights to EPI-7386, the testing of
new antiandrogen combinations with EPI-7386, the treatments under Cohort 1 and Cohort 2 of the Phase 1 clinical trial, the Phase 1b dose
expansion study and the Window of Opportunity Study, and the Company’s expected cash runway into 2025.
Forward-looking statements and information are subject
to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may
cause ESSA’s actual results, performance or achievements to be materially different from those expressed or implied thereby. Such
statements reflect ESSA’s current views with respect to future events, are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently
subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. In
making forward looking statements, ESSA may make various material assumptions, including but not limited to (i) the accuracy of ESSA’s
financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary regulatory approvals; and (iv) general
business, market and economic conditions.
Forward-looking information is developed based on assumptions
about such risks, uncertainties and other factors set out herein and in ESSA’s Annual Report on Form 10-K dated December 13, 2022
under the heading “Risk Factors”, a copy of which is available on ESSA’s profile on EDGAR at www.sec.gov.com
and on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on
ESSA’s EDGAR and SEDAR profiles. Forward-looking statements are made based on management's beliefs, estimates and opinions on the
date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions
or other circumstances should change, except as may be required by applicable United States and Canadian securities laws. Readers are
cautioned against attributing undue certainty to forward-looking statements.
ESSA PHARMA INC.
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS
(Unaudited)
Amounts in thousands of United States dollars
| |
June 30,
2023 | |
September 30, 2022 |
| |
| |
|
Cash and cash equivalents | |
$ | 38,467 | | |
$ | 57,076 | |
Prepaids and other assets | |
| 115,183 | | |
| 112,429 | |
| |
| | | |
| | |
Total assets | |
$ | 153,650 | | |
$ | 169,505 | |
| |
| | | |
| | |
Current liabilities | |
| 3,407 | | |
| 2,310 | |
Long-term debt | |
| — | | |
| 76 | |
Shareholders' equity | |
| 150,243 | | |
| 167,118 | |
| |
| | | |
| | |
Total liabilities and shareholders’ equity | |
$ | 153,650 | | |
$ | 169,505 | |
ESSA PHARMA INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS
(Unaudited)
Amounts in thousands of United States dollars, except
share and per share data
| |
|
Three months ended June 30, 2023 |
| |
|
Three months ended June 30, 2022 |
| |
|
Nine months ended June 30, 2023 |
| |
|
Nine months ended June 30, 2022 |
|
| |
| |
| |
| |
|
OPERATING EXPENSES | |
| | | |
| | | |
| | | |
| | |
Research and development | |
$ | 6,271 | | |
$ | 6,395 | | |
$ | 16,096 | | |
$ | 20,064 | |
Financing costs | |
| 2 | | |
| 3 | | |
| 6 | | |
| 11 | |
General and administration | |
| 2,639 | | |
| 2,896 | | |
| 8,889 | | |
| 9,775 | |
| |
| | | |
| | | |
| | | |
| | |
Total operating expenses | |
| (8,912 | ) | |
| (9,294 | ) | |
| (24,991 | ) | |
| (29,850 | ) |
| |
| | | |
| | | |
| | | |
| | |
Gain on derivative liability | |
| — | | |
| 2 | | |
| — | | |
| 20 | |
Interest and other items | |
| 1,613 | | |
| 419 | | |
| 3,892 | | |
| 1,005 | |
| |
| | | |
| | | |
| | | |
| | |
Net loss before taxes | |
| (7,299 | ) | |
| (8,873 | ) | |
| (21,099 | ) | |
| (28,825 | ) |
Income tax expense (recovery) | |
| — | | |
| 46 | | |
| (2 | ) | |
| 46 | |
| |
| | | |
| | | |
| | | |
| | |
Net loss for the period | |
$ | (7,299 | ) | |
$ | (8,827 | ) | |
$ | (21,101 | ) | |
$ | (28,779 | ) |
OTHER COMPREHENSIVE LOSS | |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Unrealized gain (loss) on short-term investments | |
| 43 | | |
| (3 | ) | |
| 13 | | |
| (52 | ) |
| |
| | | |
| | | |
| | | |
| | |
Loss and comprehensive loss for the period | |
$ | (7,256 | ) | |
$ | (8,830 | ) | |
$ | (21,088 | ) | |
$ | (28,831 | ) |
| |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Basic and diluted loss per common share | |
$ | (0.17 | ) | |
$ | (0.20 | ) | |
$ | (0.48 | ) | |
$ | (0.65 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average number of common shares outstanding | |
| 44,092,374 | | |
| 44,059,700 | | |
| 44,085,941 | | |
| 44,026,502 | |
Company Contact
David Wood, Chief
Financial Officer
ESSA Pharma Inc.
Contact: (778)
330-0962
Email: dwood@essapharma.com |
|
v3.23.2
Cover
|
Aug. 08, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 08, 2023
|
Entity File Number |
001-37410
|
Entity Registrant Name |
ESSA Pharma Inc.
|
Entity Central Index Key |
0001633932
|
Entity Tax Identification Number |
98-1250703
|
Entity Incorporation, State or Country Code |
A1
|
Entity Address, Address Line One |
Suite 720
|
Entity Address, Address Line Two |
999 West Broadway
|
Entity Address, City or Town |
Vancouver
|
Entity Address, State or Province |
BC
|
Entity Address, Country |
CA
|
Entity Address, Postal Zip Code |
V5Z 1K5
|
City Area Code |
778
|
Local Phone Number |
331-0962
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Shares, no par value
|
Trading Symbol |
EPIX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionISO 3166-1 alpha-2 country code.
+ References
+ Details
Name: |
dei_EntityAddressCountry |
Namespace Prefix: |
dei_ |
Data Type: |
dei:countryCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
ESSA Pharma (NASDAQ:EPIX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
ESSA Pharma (NASDAQ:EPIX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024